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subsequent decisions by FJC.METHODS:We examined all IQWiG assessments and
corresponding FJC decisions up to 01.06.2012 regarding possible disagreements.
Afterwards we categorized these findings and tried to identify schemes where FJC
regularly deviates from IQWiG’s recommendations. We excluded decisions on Or-
phan drugs because of the special regulations for these drugs. RESULTS: Totally 13
newly launched products were evaluated by IQWiG with subsequent decision on
additional benefit by the FJC. An additional benefit is not proven for more than 70%
of patient groups. The extent of the additional benefit doesn’t differ between as-
sessment and decision in 8 products. The FJC merges patient populations being
separately analyzed by IQWiG in 4 drugs. In case of Eribulin the result of IQWiG
assessment is no additional benefit in both subgroups whereas the FJC decides on
a slight and smaller benefit in the subgroups. Deviations in number of patients and
costs can’t be assessed, because IQWiG doesn’t always provide information on
these. CONCLUSIONS: Besides one case there are minor differences between as-
sessments and subsequent decisions. The impact of these differences on the price
negotiations is unknown until now.
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CROSS-FUNTIONAL CHALLENGES IN THE PREPARATION OF A BENEFIT DOSSIER
Schmitter S1, Hartge M2, Zibell G2, Schiffner-Rohe J1
1Pfizer Deutschland GmbH, Berlin, Germany, 2Pfizer Pharma GmbH, Berlin, Germany
OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. This assessment is based on a dossier submitted by
the manufacturer for which the Federal Joint Committee (FJC) provides a detailed
template. The objective is to investigate the challenges within a pharmaceutical
company occurring during the preparation of a dossier. METHODS: First, the tem-
plate of FJC is analyzed to identify the data and skills needed to fulfill the require-
ments. These requirements are then linked to specialized departments within the
company. Finally, governance principles are developed. RESULTS: Data regarding
drug and disease, available treatments and guidelines, clinical study program as
well as German epidemiology and cost are needed for the dossier. Consequently,
profound skills in medicine, evidence-based medicine and biometrics are neces-
sary to support medical writing of the dossier. The departments Medical, Health
Economics & Outcomes Research (HEOR), Market Access, Regulatory, Commercial
and Legal are crucial for the development of a successful dossier. To finalize the
dossier in time, two teams are defined: One operational team with delegates from
Medical, HEOR and Regulatory prepares the dossier according to the FJC-require-
ments with or without support by an external vendor. Strategic decisions including
aspects not confined to the individual product are taken by the cross-functional
governance board. Beyond this a close alignment with global and regional Access
policies is essential. CONCLUSIONS: The preparation of a benefit dossier requires a
new area of cooperation at the local level within pharmaceutical companies involv-
ing a cross-functional team. Of particular importance are the HEOR and Regulatory
departments where essential information and expertise reside, putting these team
in the spotlight.
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PROPOSED AND ACTUAL BUREAUCRATIC BURDEN OF HTA SUBMISSIONS TO
THE INDUSTRY- CASE STUDIES FROM GERMANY AND UK
Schweikert B1, Jonsson L2
1OptumInsight, Munich, Germany, 2OptumInsight, Stockholm, Sweden
OBJECTIVES: To assess the effort it takes for manufacturers to develop HTA sub-
missions in Germany and the UK and to compare it to the estimates proposed by
the legislator. METHODS: A review on available sources was conducted to assess
the proposed as well as the actual effort it takes to develop and submit a dossier to
the HTA agencies in Germany (G-BA/ IQWiG) and UK (NICE). Evidence from the
review was supplemented by interviews with experts from pharmaceutical and
consulting industry. RESULTS: The time proposed for HTA submission was partic-
ular low in Germany were the legislator estimated that a submission to the G-BA/
IQWiG could be done within 2.5 days. However, according to the review and expert
judgment actual effort of HTA submission in Germany required a minimum of one
year for multidisciplinary teams collaborating on generation of evidence following
the exact guidance that details the methods, contents, and format of submissions
to the German HTA body. Effort in UK is seen as lower due to the more collaborative
and interactive nature of the process avoiding unnecessary effort and allowing for
a clear focus on the critical questions. However, since the process in Germany is
still fairly new, it could be assumed that due to learning curve effort will be lower in
subsequent submission as the process gets more rationalized. CONCLUSIONS: The
actual burden exceeds the burden that was estimated particularly in Germany by
magnitudes. This study shows that the burden also depends on the organization of
the consulting process during dossier development. Whereas the early and struc-
tured interaction in UK was seen as favorable to avoid spending time on aspects
that are not relevant for the decision of the HTA body the highly formalized Ger-
man process where such an action is much less intense requires a more mecha-
nistic approach.
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BENEFITS OF PROBABALISTIC SENSITIVITY ANALYSIS
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OBJECTIVES: Since 2004 the National Institute of Health and Clinical Excellence
requires manufacturers to conduct a probabilistic sensitivity analysis for their
technology appraisals. The objective of this review is to assess the outcomes of
different probabilities of being cost effective and compare this with the actual
decision making done by NICE.METHODS: The search term “probabilistic sensitiv-
ity analysis” was used on NICE homepage (2012-01-25). The chapters included in
the search was assessed and included for further review if a probability of being
cost effective was provided regardless of what threshold was mentioned. If several
probabilities were provided the number provided by the evidence review group
were used rather than those provided by the manufacturer since these numbers
are more likely to be used in the decision making. If several scenarios were pre-
sented the base case scenario was chosen. Finally the probabilities of being cost
effective versus was compared with the actual decision making which could result
in 2 outcomes either it was recommended or not recommended. The results were
plotted into a graph to illustrate the relationship between PSA outcomes versus
final recommendation. The assessments were ranked according to their probabil-
ity of being cost effective. RESULTS: Thirty-one assessments were included for
final review. A higher probability of a technology being cost effective correlated to
more positive decision making and there even is observed a clear threshold where
technologies with a 40% certainty of being cost effective tend to be recommended
(3 out of 20) whereas those below are not recommended (2 out of 11) irrespective of
ICER. CONCLUSIONS: Reports suggested that ICER estimate was not a robust driver
of decision making. NICE applicant should provide an increase attention to PSA on
the top of ICER estimate.
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INTEGRATION OF VALUE OF INFORMATION INTO THE DECISION MAKING
PROCESS IN IRELAND
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In Ireland, the National Centre for Pharmacoeconomics (NCPE) appraises the cost
effectiveness of technologies in response to requests from the Health Service Ex-
ecutive (HSE). A large number of reimbursement decisions are based upon the
appraisal of company Health Technology Assessments (HTAs). HTAs are con-
ducted in accordance with existing agreed Irish HTA Guidelines. These guidelines
do not specify the requirement of Expected Value of Perfect Information (EVPI)
analysis. OBJECTIVES: To examine the application of EVPI analysis as part of the
formal HTA process. METHODS: There is no set cost-effectiveness threshold in
Ireland; however, technologies with ICERs  €20,000/QALY are less likely to be
reimbursed. This threshold was considered here. EVPI estimates (at €20,000/QALY)
were determined directly from the PSA results of company economic models. Es-
timates were scaled up to 10 year population EVPI (PEVPI) levels. NCPE recommen-
dations on reimbursement were recorded. RESULTS: The NCPE have estimated
PEVPI values on nine company economic evaluations to date. All evaluations were
for newly licensed technologies; eight were pharmaceuticals and one was a diag-
nostic. Two technologies had ICERs €120,000 with PEVPI estimates €20 million;
reimbursement was not recommended. Two technologies dominated the relevant
comparators and one had an ICER €10,000/QALY. All PEVPI values were below €1
million. Reimbursement of all three technologies was recommended. The four
remaining technologies had ICERs in the range of €21,000/QALY -€30,000/QALY;
their PEVPI values ranged from about €1.5 million - €35 million. Reimbursement
was not recommended. In two cases (original PEVPI values of €2.4 million and €35
million respectively) the manufacturer subsequently revised the price. Reimburse-
ment was then recommended. There was no formal reanalysis of PEVPI.
CONCLUSIONS: To date, the formal analysis of PEVPI has not affected the decision
to accept or reject technologies with ICERs lower and higher than €20,000/QALY
respectively.
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REVIEW OF NICE’S TECHNOLOGY APPRAISAL RECOMMENDATIONS
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National Institute for Health and Clinical Excellence, Holborn, London, UK
OBJECTIVES: To illustrate how decision-making in England and Wales is influ-
enced by cost effectiveness and other factors, with particular emphasis on deci-
sions for end-of-life treatments. METHODS: An analysis of all technology apprais-
als published by the National Institute for Health and Clinical Excellence (NICE)
from 1st March 2000 to 31st May 2012 was conducted, with recommendations
categorised as ‘recommended’, ‘optimised, ‘not recommended’, ‘only in research’
and ‘non-submission’, by therapeutic area and by technology process (multiple
technology appraisal or single technology appraisal). These categories were then
mapped against the most plausible cost per QALY estimate and the recommenda-
tions were contextualised with the factors used in decision-making. RESULTS:
Since March 2000, NICE has published 256 appraisals containing 482 individual
recommendations on the use of technologies in England and Wales. The majority
(78%) of these decisions recommended the use of a technology either in line with its
licensed indication (‘recommended’) or under specific conditions (‘optimised’).
‘Only in research’ and ‘not recommended’ decisions represented 5% and 14% of all
recommendations respectively. Of the 135 recommendations in technology ap-
praisals which considered the use of oncology treatments, 61% were ‘recom-
mended’ or ‘optimised’. Since January 2009, 15 end-of-life technologies have been
considered of which 9 were recommended because the additional weight that
needed to be assigned to the QALY benefits was acceptable to justify these as an
appropriate use of NHS resources. Examples from other therapeutic areas show
how factors other than cost effectiveness have affected the recommendations,
such as equality considerations, or the impact of health-related benefits not cap-
tured in the QALY. CONCLUSIONS: NICE has provided guidance on a wide range of
new and established technologies, with the majority recommended for use. The
starting point for the decisions is the ICER in line with NICE’s commitment to
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support the cost-effective use of NHS resources, but other factors regularly influ-
ence decision-making.
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ASSESSING THE QUALITY OF MANUFACTURERS’ SEARCHES IN NICE SINGLE
TECHNOLOGY APPRAISALS BY EVIDENCE REVIEW GROUPS
Wong R, Paisley S, Carroll C
The University of Sheffield, Sheffield, UK
OBJECTIVES: No guidelines exist in the approach that Evidence Review Groups
(ERGs) should take to appraise search methodologies in the manufacturer’s sub-
mission (MS) in single technology appraisals (STA). As a result, ERGs are left to
appraise searches using their own approach. This study investigates the limita-
tions of manufacturers’ search methodologies as critiqued by ERGs in published
STA reports. METHODS: Limitations from search critiques in 83 ERG reports pub-
lished in the NIHR website between 2006 and May 2011 were extracted. The limi-
tations were grouped into themes. Comparisons were made between limitations
reported in the clinical effectiveness versus cost-effectiveness searches. RESULTS:
Over 60 different limitations were identified and sorted in seven broad themes:
missing studies, search strategy, reporting, sources, limits, filters and translation.
The search strategy theme contained the most limitations. Missing studies were
frequently found by the ERG group in the clinical effectiveness searches. The omis-
sion of searches by manufacturers for unpublished and ongoing trials was fre-
quently reported by the ERG. By contrast, failure of the manufacturer to report
strategies was the most common limitation in the cost-effectiveness searches
which may explain the number of missing critiques in some ERG reports. Themes
with the most frequent limitations in both types of searches are search strategy,
reporting and source. CONCLUSIONS: Variations exist in the limitations reported
in both clinical and cost-effectiveness evidence searches in STAs. It is recom-
mended that separate checklists or one that incorporates both reporting and
search strategy appraisal be used to ensure that ERG groups and manufacturers are
aware of the range of limitations that might exist when appraising searches.
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PAYER INFORMATION REQUIREMENTS FOR RELATIVE EFFECTIVENESS
ASSESSMENT VARY ACROSS MARKETS AND CREATE DISCREPENCIES IN
PATIENT ACCESS TO MEDICINES
Marinoni G1, Lockwood C1, Honoré AC1, Rodrigues T1, Izmirlieva M1, Walker S1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK
OBJECTIVES: To 1) evaluate how relative effectiveness assessment (REA) is used
within the national pricing and reimbursement (P&R) processes in 8 developed and
emerging markets; 2) to understand payer REA requirements and preferences in
each of the markets studied; and 3) to analyse how the process impacts patient
access to medicines across geographies. METHODS: IHS studied national P&R pro-
cesses through primary and secondary research to establish how REA is leveraged
to rationalise reimbursement and control price levels. Over 30 key relative effec-
tiveness assessors and P&R decision makers were interviewed to understand the
level and type of relative effectiveness evidence they look for in practice, broken
down by public versus private sector, primary versus secondary-care segment, and
key therapeutic areas. This research was further supported by real-life REA case
studies across key therapeutic areas. RESULTS: The evaluation of the therapeutic
value of a medicine can result in P&R decision discrepancies across markets. These
coverage disparities notably reflect societal and methodological differences in the
way the available evidence is interpreted across markets. In terms of how thera-
peutic value is factored into P&R decisions, markets can be segmented into two
broad categories: 1) those that rely on economic evaluation to assess therapeutic
value, and 2) those that evaluate the added therapeutic value/improvement in
actual clinical benefit without considering associated costs. In terms of informa-
tion needs, payers wish to be in a position to evaluate how new medicines compare
with the standard of care in their specific health care setting and in their patient
population when making their P&R decisions. CONCLUSIONS: REA will increas-
ingly be used in future to rationalise finite health care resources and budgets. For
now there are two schools when it comes to the methodology and patient access to
medicines is more stringent in countries that undertake economic evaluation.
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EXPLORING THE ROLE OF THE COMMITTEE IN THE NICE APPRAISAL PROCESS:
HOW CONSISTENT ARE DECISIONS ACROSS COMMITTEES?
McCann E, Plested M
HERON, Luton, UK
OBJECTIVES: NICE technology appraisals are reviewed by one of four committees
(A to D). Given the standard submission template, the information submitted as
part of the appraisal process is the same across submissions. Therefore, commit-
tees may be expected to make similar decisions regarding the acceptance or rejec-
tion of submissions. This research explored whether there were differences in
acceptances or rejections between committees and which factors affected those
decisions. METHODS: Final appraisal determinations (FADs) from October 2009 to
May 2012 were identified and reviewed. The committee, decision, and reasons for
the decision were extracted from the FADs. Rates of acceptance or rejection were
compared across the four committees using Fisher’s exact test. The composition of
each committee and the considered therapy area were also assessed. RESULTS:
This research considered 53 submissions, from which 63 recommendations were
generated. Committee A made the highest proportion of positive recommenda-
tions (75%) and Committee D made the lowest proportion (50%). The background of
committee members was similar between Committees A and B, and between C and
D, but differed between those two sets. However, the number of acceptances or
rejections did not differ significantly by committee (p0.560). Limitations in clini-
cal evidence were cited as a reason for rejection more frequently than limitations
in economic evidence across all committees. The considered therapy areas differed
between committees though cancer was the most commonly-appraised area;
Committee C reviewed the highest proportion of cancer submissions. For this ther-
apy area, the rate of acceptance or rejection did not differ significantly by commit-
tee (p0.126). CONCLUSIONS: The likelihood of positive or negative recommenda-
tions did not appear to vary by the committee assessing the submission. Given the
reasons for negative recommendations and the proportion of academic committee
members, maximising the quality and rigour of submitted evidence is a rational
approach to the appraisal process.
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THE ROLE OF DECISION-ANALYTIC MODELING IN GERMAN HEALTH
TECHNOLOGY ASSESSMENTS
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OBJECTIVES: Decision-analytic modeling has become a widespread method ap-
plied in Health Technology Assessments (HTA), but the extent to which modeling
is used differs widely among international HTA institutions. The German Agency
for Health Technology Assessment (DAHTA) states in its methodological guidelines
that model calculations can be carried out if necessary and feasible. However,
DAHTA does not provide any methodological guidance in this regard. Aim of this
study is to quantify the current role of decision-analytic modeling in DAHTA-re-
ports and to analyze the applied methods. METHODS: All 140 DAHTA-reports pub-
lished between 1998 and May 2011 were screened for the specific development of
new decision-analytic models. To assess the impact of these models on recom-
mendations, all relevant reports were reviewed with respect to the health eco-
nomic conclusion, modeling methods and further research needs. RESULTS: A
total of 90 DAHTA-reports incorporate an economic assessment. Of these, ten re-
ports develop a new specific decision-analytic model. About 30% of the reports
without a model come to a general economic conclusion but only one report gives
a clear recommendation without major limitations. About 20% of these reports
explicitly state that the development of a model for the German setting may have
helped to come to a clear conclusion. In contrast, all reports incorporating a model
give an economic recommendation – two of these with limitations. The identified
models differ with respect to the type of health economic evaluation (cost-effec-
tiveness, cost-utility), model type (decision tree, Markov model, Monte Carlo sim-
ulation), time horizon (two weeks – life long), discount rate (3%, 5%), perspective
(statutory health insurance, care provider, social), outcome parameters (generic,
disease specific) and sensitivity analyses (one-way, multi-way, probabilistic).
CONCLUSIONS: Incorporating decision-analytic models in German HTAs has the
potential to increase the number of health economic recommendations, but only a
fraction of reports developed a specific model so far.
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OBJECTIVES: To estimate the useful life of Computerised Tomography Equipment
(CT) METHODS: A main components analysis in this methodology has allowed for
a reduction in the number of variables on the survey-file in Computerised Tomog-
raphy technology and facilitates subsequent work without a significant loss of
information. The Log Binomial Regression Model has enabled probability calcula-
tions on answers (technology leap) to the different levels of stimuli (changes in
variables, temporary development, detection system, imaging resolution and
equipment power). Using a Discriminant analysis, the objective has been to esti-
mate, based on time, the chances of a technological leap occurring. RESULTS: The
18 evaluated technical parameters in Computerised Tomography Technology have
been grouped in three main components: Detection System which explains 72.4% of
the variance; Imaging Resolution which explaining 13.55% of the variance and Equip-
ment Power explaining 7.1% of the variance. Logistic regression allows us to approx-
imate the influence of each main component with the passing of time, the imple-
mentation of a technology leap, with its significant influence with positive signs of
temporary evolution (0.430), and with a negative sign for the main component the
detection system(3.974), image resolution (3.766) and equipment power
(2.460). For Determinant analysis, the explanatory variables used in the model are
the 3 components calculated. The prediction model obtains a lower percentage of
success than the Log Binomial, around 66.7%. The most important factor in influ-
encing the change of technology seems to be the image resolution followed by the
detection system and a negative sing for temporary evolution. CONCLUSIONS: The
results of the present project will enable advance knowledge of the expectations of
technological change in CT technology, allowing an advance in investment plan-
ning for this technology, for acquiring and installing this type of technology.
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COMPARING THE HUNGARIAN METHODOLOGICAL GUIDELINE FOR
CONDUCTING ECONOMIC EVALUATION OF HEALTH CARE INTERVENTION
WITH EUROPEAN GUIDELINES
Huszti Z, Nagy BZ
National Institute for Quality- and Organizational Development in Healthcare and Medicines,
Budapest, Hungary
OBJECTIVES: The Hungarian methodological guideline for conducting economic
evaluation of health care interventions was published in 2002 and the modified
version will be shortly published. The 10thanniversary of the Hungarian HTA
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